Drugs / MYDICAR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 1 met primary | ||||||
| Phase 1/2 | NCT02346422 | Apr → Jun 2015 | cardiomyopathy, heart failure | Celladon Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00454818 | Mar 2007 → Aug 2010 | congestive heart failure, dilated cardiomyopathy | Celladon Corporation | Completed | Met primary |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01966887 | Dec 2013 → Sep 2015 | cardiomyopathy, congestive heart failure | Assistance Publique - Hôpitaux de Paris | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MYDICAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01966887 ↗ |
| Action | Restore | “restore SERCA2a function” NCT00454818 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “using a recombinant adeno-associated viral vector (AAV)” NCT00454818 ↗ |
| Route | Other | “administered by antegrade epicardial coronary artery infusion” NCT00454818 ↗ |